The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1415
April 29, 2013
View Complete Issue         Table of Contents 2019 
Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia
April 29, 2013 (Issue: 1415)
An extended-release injectable formulation of the second-generation antipsychotic aripiprazole (Abilify) has been approved by the FDA (Abilify Maintena – Otsuka/Lundbeck) for once-monthly treatment of schizophrenia. It is the fourth...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia
Article code: 1415b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.